Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monoclonal antibody (mAb) tagitanlimab for the first-line treatment of advanced or metastatic non-small cell lung...
HoneyNaps Launches Cloud Version of AI Sleep Diagnostic Software “SOMNUM™” at SLEEP 2025
HIPAA-compliant cloud-based service provides diagnostic reports via the web with no installation required AI-powered trial service offered, highlighting potential for hospital-specific integration Presented performance of heart rate-based sleep stage estimation algorithm through oral and poster presentations BOSTON, Aug. 19, 2025 /PRNewswire/ -- HoneyNaps, a medical AI diagnostics company, showcased both its technological capabilities and research achievements at...
Dubai Humanitarian: Powerful New Documentary Reveals World’s Largest Humanitarian Logistics Hub
- 'Coming Together: The Dubai Humanitarian Story' provides behind-the-scenes look inside the heart of global disaster response facility - Launches on World Humanitarian Day, 19 August 2025 - First six months of 2025 saw $48.8m humanitarian aid distributed from Dubai Humanitarian, reflected in its Humanitarian Logistics Databank DUBAI, UAE, Aug. 19, 2025 /PRNewswire/ -- Dubai Humanitarian, the world's largest humanitarian...
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately. Nilesh Shah, Head of Region, AMEA, Illumina Nilesh brings over 25 years of...
Antengene’s ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation...
Tigermed Receives MSCI ESG AAA Rating
HANGZHOU, China, Aug. 19, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI's AAA rating is reserved for companies that demonstrate superior...
Tigermed Receives MSCI ESG AAA Rating
HANGZHOU, China, Aug. 19, 2025 /PRNewswire/ -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI's AAA rating is reserved for companies that demonstrate superior...
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world. In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001) through six months (180 days). , Administration...
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive...
openRxiv names Dr. Tracy Teal first CEO to advance open science
Scientist and nonprofit leader who previously led The Carpentries and Dryad to lead the organization that oversees bioRxiv and medRxiv. DAVIS, Calif., Aug. 19, 2025 /PRNewswire/ -- openRxiv announced today that after an extensive international search, its Board of Directors has appointed Dr. Tracy Teal as the organization's inaugural CEO. Dr. Teal has served as interim COO of openRxiv...
